Modeling and Simulation of Adherence: Approaches and Applications in Therapeutics

Overview

Journal AAPS J

Specialty Pharmacology

Date 2005 Dec 16

PMID 16353919

Citations 17

Authors

Leslie A Kenna

Line Labbe

Jeffrey S Barrett

Marc Pfister

Affiliations

Soon will be listed here.

Abstract

Partial adherence with a prescribed or randomly assigned dose gives rise to unintended variability in actual drug exposure in clinical practice and during clinical trials. There are tremendous costs associated with incomplete and/or improper drug intake-to both individual patients and society as a whole. Methodology for quantifying the relation between adherence, exposure and drug response is an area of active research. Modeling and statistical approaches have been useful in evaluating the impact of adherence on therapeutics and in addressing the challenges of confounding and measurement error which arise in this context. This paper reviews quantitative approaches to using adherence information in improving therapeutics. It draws heavily on applications in the area of HIV pharmacology.

Citing Articles

Solving the Evidence Interpretability Crisis in Health Technology Assessment: A Role for Mechanistic Models?.

Courcelles E, Boissel J, Massol J, Klingmann I, Kahoul R, Hommel M Front Med Technol. 2022; 4:810315.

PMID: 35281671 PMC: 8907708. DOI: 10.3389/fmedt.2022.810315.

Study protocol for iSIPsmarter: A randomized-controlled trial to evaluate the efficacy, reach, and engagement of a technology-based behavioral intervention to reduce sugary beverages among rural Appalachian adults.

Zoellner J, Porter K, You W, Reid A, Frederick C, Hilgart M Contemp Clin Trials. 2021; 110:106566.

PMID: 34492306 PMC: 8595813. DOI: 10.1016/j.cct.2021.106566.

Approaches to handling missing or "problematic" pharmacology data: Pharmacokinetics.

Irby D, Ibrahim M, Dauki A, Badawi M, Illamola S, Chen M CPT Pharmacometrics Syst Pharmacol. 2021; 10(4):291-308.

PMID: 33715307 PMC: 8099444. DOI: 10.1002/psp4.12611.

When Multiple Objective Measures of Medication Adherence Indicate Incongruent Adherence Results: An Example with Pediatric Cancer.

Cain C, Meisman A, Drucker K, Isaac E, Verma T, Griffin J Int J Environ Res Public Health. 2020; 17(6).

PMID: 32192028 PMC: 7142654. DOI: 10.3390/ijerph17061956.

Temporal Factors and Missed Doses of Tuberculosis Treatment. A Causal Associations Approach to Analyses of Digital Adherence Data.

Stagg H, Lewis J, Liu X, Huan S, Jiang S, Chin D Ann Am Thorac Soc. 2019; 17(4):438-449.

PMID: 31860328 PMC: 7175980. DOI: 10.1513/AnnalsATS.201905-394OC.

References

Simons L, LEVIS G, Simons J . Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust. 1996; 164(4):208-11. DOI: 10.5694/j.1326-5377.1996.tb94138.x. View

Sheiner L, Rubin D . Intention-to-treat analysis and the goals of clinical trials. Clin Pharmacol Ther. 1995; 57(1):6-15. DOI: 10.1016/0009-9236(95)90260-0. View

Girard P, Sheiner L, Kastrissios H, Blaschke T . Do we need full compliance data for population pharmacokinetic analysis?. J Pharmacokinet Biopharm. 1996; 24(3):265-82. DOI: 10.1007/BF02353671. View

de Klerk E, Van Der Linden S . Compliance monitoring of NSAID drug therapy in ankylosing spondylitis, experiences with an electronic monitoring device. Br J Rheumatol. 1996; 35(1):60-5. DOI: 10.1093/rheumatology/35.1.60. View

Goldie S, Paltiel A, Weinstein M, Losina E, Seage 3rd G, Kimmel A . Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med. 2003; 115(8):632-41. DOI: 10.1016/j.amjmed.2003.07.007. View

Lu J, Gries J, Verotta D, Sheiner L . Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance. J Pharmacokinet Pharmacodyn. 2001; 28(4):343-62. DOI: 10.1023/a:1011582713692. View

Girard P, Blaschke T, Kastrissios H, Sheiner L . A Markov mixed effect regression model for drug compliance. Stat Med. 1998; 17(20):2313-33. DOI: 10.1002/(sici)1097-0258(19981030)17:20<2313::aid-sim935>3.0.co;2-v. View

Morris S, Groom G, Cameron E, Buckingham M, Everitt J, Elstein M . Studies on low dose oral contraceptives: plasma hormone changes in relation to deliberate pill ('Microgynon 30') omission. Contraception. 1979; 20(1):61-9. DOI: 10.1016/0010-7824(79)90045-3. View

Hardy E, Kumar S, Peaker S, Feely M, Pullar T . A comparison of a short half-life marker (low-dose isoniazid), a long half-life pharmacological indicator (low-dose phenobarbitone) and measurements of a controlled release 'therapeutic drug' (metoprolol, Metoros) in reflecting incomplete compliance.... Br J Clin Pharmacol. 1990; 30(3):437-41. PMC: 1368147. DOI: 10.1111/j.1365-2125.1990.tb03795.x. View

10.

Urquhart J, de Klerk E . Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens. Stat Med. 1998; 17(3):251-67; discussion 387-9. DOI: 10.1002/(sici)1097-0258(19980215)17:3<251::aid-sim762>3.0.co;2-a. View

11.

Larsen J, Andersen M, Kragstrup J, Gram L . High persistence of statin use in a Danish population: compliance study 1993-1998. Br J Clin Pharmacol. 2002; 53(4):375-8. PMC: 1874277. DOI: 10.1046/j.1365-2125.2002.01563.x. View

12.

Pfister M, Labbe L, Hammer S, Mellors J, Bennett K, Rosenkranz S . Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother. 2002; 47(1):130-7. PMC: 148981. DOI: 10.1128/AAC.47.1.130-137.2003. View

13.

MEREDITH P, Elliott H . Therapeutic coverage: reducing the risks of partial compliance. Br J Clin Pract Suppl. 1994; 73:13-7. View

14.

Cramer J, Mattson R, Prevey M, Scheyer R, Ouellette V . How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989; 261(22):3273-7. View

15.

Detry J . Patient compliance and therapeutic coverage: amlodipine versus nifedipine SR in the treatment of hypertension and angina: interim results. Steering Committee and Cardiologists and General Practitioners involved in the Belgium Multicentre Study on.... Clin Cardiol. 1994; 17(9 Suppl 3):III12-6. View

16.

Hyland M, Kenyon C, Allen R, Howarth P . Diary keeping in asthma: comparison of written and electronic methods. BMJ. 1993; 306(6876):487-9. PMC: 1676776. DOI: 10.1136/bmj.306.6876.487. View

17.

Urquhart J . Role of patient compliance in clinical pharmacokinetics. A review of recent research. Clin Pharmacokinet. 1994; 27(3):202-15. DOI: 10.2165/00003088-199427030-00004. View

18.

Volmink J, Garner P . Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev. 2001; (4):CD003343. DOI: 10.1002/14651858.CD003343. View

19.

Lee J, Kusek J, Greene P, Bernhard S, Norris K, Smith D . Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Am J Hypertens. 1996; 9(8):719-25. DOI: 10.1016/0895-7061(96)00056-8. View

20.

Pekovic V, Mayanja H, Vjecha M, Johnson J, Okwera A, Nsubuga P . Comparison of three composite compliance indices in a trial of self-administered preventive therapy for tuberculosis in HIV-infected Ugandan adults. Uganda-Case Western Reserve University Research Collaboration. J Clin Epidemiol. 1998; 51(7):597-607. DOI: 10.1016/s0895-4356(98)00033-x. View